Washington, D.C. 20549




(Rule 14d-101)




(Amendment No. 2)



Forty Seven, Inc.

(Name of Subject Company)



Forty Seven, Inc.

(Name of Person Filing Statement)




(Title of Class of Securities)


34983P 104

(CUSIP Number of Class of Securities)


Mark A. McCamish, M.D.

President and Chief Executive Officer

Forty Seven, Inc.

1490 O’Brien Drive, Suite A

Menlo Park, California 94025

(650) 352-4150

(Name, address and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)


With copies to:


Jamie Leigh

Eric C. Jensen
John T. McKenna
Ben Beerle
Cooley LLP
101 California St, 5th Floor
San Francisco, CA 94111
(415) 693-2000



o            Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.







This Amendment No. 2 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the “Schedule 14D-9”) previously filed by Forty Seven, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission on March 10, 2020, relating to the tender offer by Toro Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead Sciences, Inc., a Delaware corporation (“Gilead”), to purchase all of the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Shares” and each, a “Share”) at a price per Share of $95.50, net to the seller in cash, without interest and subject to any withholding of tax, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated March 10, 2020, as it may be amended or supplemented from time to time, and the related Letter of Transmittal, as it may be amended or supplemented from time to time (together with the Offer to Purchase, the “Offer”).  Any capitalized term used and not otherwise defined herein shall have the meaning ascribed to such term in the Schedule 14D-9.


Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment No. 2.  This Amendment No. 2 is being filed to reflect certain updates as set forth below.


Item 8.   Additional Information.


Item 8 “Additional Information” of the Schedule 14D-9 is hereby amended and restated by deleting the sentence under the section entitled “Legal Proceedings” on page 41 and replacing it with the following paragraphs:


On March 16 and 17, 2020, complaints were filed by purported stockholders of the Company regarding the Merger. The first complaint, filed on an individual basis by the plaintiff, is captioned Stephen Bushanksy v. Forty Seven, Inc. et al., Case No. 3:20-cv-01853 (N.D. Cal. filed Mar. 16, 2020). The second complaint, filed as a putative class action, is captioned Joseph Post v. Forty Seven, Inc., et al., No. 1:20-cv-00377 (D. Del. filed Mar. 17, 2020) (collectively, the “Complaints”). The Complaints name as defendants the Company and each member of the Company Board. The Post complaint additionally names as defendants Gilead and Purchaser. The Complaints allege violations of Section 14(e) of the Securities and Exchange Act of 1934 (the “Exchange Act”) against all defendants, and assert violations of Section 20(a) of the Exchange Act against the individual defendants. The Post complaint additionally alleges a violation of Section 14(d) of the Exchange Act against all defendants and a violation of Section 20(a) of the Exchange Act against Gilead and Purchaser. The plaintiffs contend that the Company’s Solicitation/Recommendation Statement filed on Schedule 14D-9 on March 10, 2020 omitted or misrepresented material information regarding the Merger. The Complaints seek (i) injunctive relief preventing the consummation of the Transactions; (ii) rescissory damages or rescission in the event the Transactions are consummated; and (iii) an award of plaintiff’s expenses and attorneys’ fees. The Post complaint additionally seeks dissemination of a recommendation statement that discloses certain information requested by that plaintiff. The Company believes the claims asserted in the Complaints are without merit.


Additional lawsuits may be filed against the Company, the Company Board, Gilead and/or Purchaser in connection with the Transactions, the Schedule TO and the Schedule 14D-9.






After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.







Dated: March 17, 2020


/s/ Ann D. Rhoads



Name: Ann D. Rhoads



Title:   Chief Financial Officer